Silence Therapeutics Q2 2026 net loss narrows to $12.3M; divesiran Phase 2 dosing complete

Silence Therapeutics plc

Net loss $12.3M ($0.09/share) vs $27.4M ($0.19/share) in Q2 2025; cash $72.1M at June 30, 2026.
R&D expenses fell to $9.1M from $17.6M YoY, mainly due to zerlasiran Phase 3 readiness completion and lower personnel costs.
Divesiran Phase 2 SANRECO trial completed patient dosing in 48 phlebotomy-dependent PV patients; EHA 2026 data presented.
SLN312 (AZD1705) Phase 1 results from AstraZeneca collaboration presented at EAS 2026; favorable safety and dose-dependent lipid reductions.
Preclinical SLN365 (GPR146) and SLN098 (INHBE) programs on track for potential IND filings in 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.